A dysfunctional enzyme involved in building cancer cell membranes helps fuel tumor growth; when it's disabled or depleted in mouse models, tumors shrank significantly
A research team headed by scientists at University of California San Diego School of Medicine and the Ludwig Institute for Cancer Research at UC San Diego has identified an enzyme involved in remodeling the plasma membrane of multiple cancer cell types that is critical to both survival of tumors and their uncontrolled growth.
The finding, published in the July 11, 2019 issue of Cell Metabolism, suggests a potential target for new drugs.
"Cancers are characterized not only by major changes in their genomes, but also by profound shifts in how they take up and utilize nutrients to propel rapid tumor growth," said senior author Paul S. Mischel, MD, professor in the UC San Diego School of Medicine Department of Pathology and Ludwig member. "How do these diverse aspects fit together and can they be taken advantage of, for the benefit of patients?"
In the new study, conducted in collaboration with Benjamin Cravatt, PhD, professor at Scripps Research, and led by first author Junfeng Bi, PhD, in Mischel's lab, researchers identified an enzyme called LPCAT1, whose levels increase in cancer and which plays a key role in tumor growth by changing the phospholipid composition of the cancer cells' plasma membrane, allowing amplified and mutated growth factor signals to spur tumor growth.
Without LPCAT1, tumors cannot survive. When researchers genetically depleted LPCAT1 in multiple types of cancer in mice, including highly lethal glioblastomas (brain) and an aggressive lung cancer, malignancies shrank dramatically and survival times improved.
The results, wrote the authors, demonstrate that LPCAT1 is an important enzyme that becomes dysregulated in cancer, linking common genetic alterations in tumors with changes in their metabolism to drive aggressive tumor growth."
"Advances in DNA sequencing technologies have reshaped our understanding of the molecular basis of cancer, suggesting a new and more effective way of treating cancer patients," said Mischel. "However, to date, precision oncology has yet to benefit many patients, motivating a deeper search into understanding how genetic alterations in tumors change the way cancer cells behave, and potentially unlocking new ways to more effectively treat patients.
"These results also suggest that LPCAT1 may be a very compelling new drug target in a wide variety of cancer types."
Co-authors include: Taka-Aki Ichu and Alex Reed, Skaggs Research; Ciro Zanca, Huijun Yang, Sudhir Chowdhry, Kristen M. Turner, Wenjing Zhang and Sihan Wu, Ludwig Institute for Cancer Research; Wei Zhang, Oswald Quehenberger, Jeremy N. Rich, Webster K. Cavenee and Frank B. Furnari, UC San Diego; Yuchao Gu and Genaro R. Villa, Ludwig and UCLA; Shiro Ikegami, Chiba University; William H. Yong, Harley I. Kornblum, and Timothy F. Cloughesy, UCLA.
Disclosure: Paul Mischel is co-founder of Pretzel Therapeutics. He has equity and serves as a consultant for the company. He also did one-time consultation for Abide Therapeutics.
Scott LaFee | EurekAlert!
Observing the internal 3D structure of the nipple to understand and fight breast cancer
09.04.2020 | Nagoya University
New 3D cultured cells mimic the progress of NASH
02.04.2020 | Tokyo University of Agriculture and Technology
Digital cameras as well as many other electronic devices need light-sensitive sensors. In order to cater for the increasing demand for optoelectronic components of this kind, industry is searching for new semiconductor materials. They are not only supposed to cover a broad range of wavelengths but should also be inexpensive.
A hybrid material, developed in Dresden, fulfils both these requirements. Himani Arora, a physics PhD student at Helmholtz-Zentrum Dresden-Rossendorf (HZDR),...
The development of the first high-repetition-rate laser source that produces coherent soft x-rays spanning the entire 'water window' heralds the beginning of a new generation of attosecond technology
The ability to generate light pulses of sub-femtosecond duration, first demonstrated some 20 years ago, has given rise to an entirely new field: attosecond...
Published by Marc Tudela, Laura Becerra-Fajardo, Aracelys García-Moreno, Jesus Minguillon and Antoni Ivorra, in Access, the journal of the Institute of Electrical and Electronics Engineers
The project Electronic AXONs: wireless microstimulators based on electronic rectification of epidermically applied currents (eAXON, 2017-2022), funded by a...
The Belle II experiment has been collecting data from physical measurements for about one year. After several years of rebuilding work, both the SuperKEKB electron–positron accelerator and the Belle II detector have been improved compared with their predecessors in order to achieve a 40-fold higher data rate.
Scientists at 12 institutes in Germany are involved in constructing and operating the detector, developing evaluation algorithms, and analyzing the data.
Electrolytes play a key role in many areas: They are crucial for the storage of energy in our body as well as in batteries. In order to release energy, ions - charged atoms - must move in a liquid such as water. Until now the precise mechanism by which they move through the atoms and molecules of the electrolyte has, however, remained largely unknown. Scientists at the Max Planck Institute for Polymer Research have now shown that the electrical resistance of an electrolyte, which is determined by the motion of ions, can be traced back to microscopic vibrations of these dissolved ions.
In chemistry, common table salt is also known as sodium chloride. If this salt is dissolved in water, sodium and chloride atoms dissolve as positively or...
07.04.2020 | Event News
06.04.2020 | Event News
02.04.2020 | Event News
09.04.2020 | Life Sciences
09.04.2020 | Physics and Astronomy
09.04.2020 | Materials Sciences